Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Chipotle

OneMain Hld

ResMed

Spirit Airlines

Sales growth is an important metric for any company, as it is a vital part of growth projections and instrumental in strategic decision making.

Buy These  Five Stocks With Attractive Sales Growth Right Now

Biogen

Novartis

We examine three biotech companies' past performances and future outlooks.

3 Biotech Companies Analyzed

Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Vertex (VRTX) Might be Well Poised for a Surge

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Vertex (VRTX) Hits 52-Week High, Can the Run Continue?

Vertex Beats: How A High P/E Biotech May Be Undervalued

Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.

Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales

Don't let Vertex's current valuation fool you. This elite biotech stock is a steal at current levels.

Is Vertex Pharmaceuticals Stock Still a Strong Buy?

Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeffrey Leiden on Q4 2019 Results - Earnings Call Transcript

The company outperformed Wall Street expectations thanks to strong results from Trikafta.

Vertex Pharmaceuticals Reports Q4 Financial Earnings, Beats Estimates

Vertex Pharmaceuticals Inc. VRTX, -0.90% shares rose in the extended session Thursday after the biotech drug maker's results and forecast topped Wall Street estimates.

Vertex Pharma stock rises on earnings, outlook beat

Late Thursday, Vertex Pharmaceuticals reported adjusted income of $1.70 per share on $1.41 billion in revenue for its fourth quarter ended Dec. 31. As a result, VRTX stock popped.

Top Biotech Vertex Pops After Crushing Fourth-Quarter Expectations

Alexion Pharma

Amgen

Eli Lilly

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More

Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Why Vertex (VRTX) Might Surprise This Earnings Season

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.

Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?

CRISPR Therapeutics

Cue Biopharma

Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.

3 Biotech Start-Ups That Could Soar in 2020

The big biotech thinks it just might be able to cure type 1 diabetes.

Vertex's $950 Million Bet That Could Pay Off Big-Time for Investors

Galapagos

One of these biotechs dominates the treatment of cystic fibrosis. The other doesn't have a single FDA-approved drug -- yet.

Better Buy:  Vertex Pharmaceuticals vs. Galapagos

BeiGene

BeiGene and Vertex Pharmaceuticals aren't nearly as expensive as you may think.

2 Ultra-Expensive Biotech Stocks Still Worth Buying

Axsome Therapeutics

Seagen

Shares of these biotech companies are near their five-year highs after some strong performances in 2019.

Are Biotech Stocks Due for a Correction in 2020?

DexCom

Intuitive Surgical

Insulet

Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference.

Vertex, Dexcom, Insulet, Intuitive Surgical In Buy Range Before Healthcare Conference

Guardant Health Inc

Here are three compelling reasons to buy healthcare stocks this year.

Why Your 2020 Resolution Should Be to Buy More Healthcare Stocks

Vertex Pharmaceuticals is a bio-pharmaceutical company based in Boston, U.S. The company is one of the first bio-pharma companies that uses rational drug design, whereby its drug molecule is complementary in shape and charge to the biochemical target.

Why Has Vertex Pharmaceuticals’ Stock Gained 30% In The Last Quarter?

Vertex Pharmaceuticals (VRTX) closed at $223.79 in the latest trading session, marking a -0.11% move from the prior day.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.11%: What You Should Know

Amarin Corporation Plc

Exponential growth is on the horizon for these companies. Investors should take note.

3 High-Growth Stocks That Can Soar

Adobe

Boeing

Bristol-Myers

Salesforce

Fidelity National Information

Global Payments

Netflix

ServiceNow

For investors seeking stocks than can beat the market in 2020, Goldman Sachs has identified those with the highest projected sales growth.

News for Vertex Pharmaceuticals Stock (VRTX)